Octave Announces Publication of Analytical Validation Study Results in Nature Communications More
Octave Announces Publication of Analytical Validation Study Results in Nature Communications More
Wednesday, May 29 – Saturday, June 1
Nashville, TN
We are excited to engage with leading experts in MS at the 2024 CMSC Annual Meeting, where we’ll have the opportunity to present our innovative approach to revolutionizing care in MS and other neurodegenerative diseases.
Join us at the Octave Supporter Showcase to hear our collaborators discuss the science behind our precision care platform.
Session Description
Personalized medicine is possible for your MS patients. This session presents the Octave Multiple Sclerosis Disease Activity (MSDA) Test, which provides validated, actionable insights into disease activity.
Explore crucial research and publications that demonstrate how this multi-protein biomarker approach enhances longitudinal patient management.
Session Details
Chief of Neurology, Dallas Veterans Affairs Medical Center,
Head of MS/Neuroimmunology section
Professor- Department of Neurology UT Southwestern Medical Center
Professor of Neurosciences, UC San Diego
Vice Chair of Human Clinical Research, UC San Diego
Division Chief, Neuroimmunology, UC San Diego
Director, Rady Children’s Pediatric MS Center
We’re excited that the Octave MSDA Test results are being highlighted as part of Professor Ahmed Z. Obeidat’s Cytokind, Inc., sponsored poster that focuses on the Unmet Needs in MS. This poster is a finalist for the prestigious title of the 2024 Consortium of Multiple Sclerosis Centers’ “CMSC Neuroinnovator of the Year”. The 2024 CMSC Neuroinnovation Competition aims to recognize and celebrate original and innovative work in the field of MS research.
Presentation Description
Dr. Obeidat will present, Background, Advances, and Design of the Phase 2 Randomized Trial of @Home Phototherapy for MS, the “Silent Symptoms Trial,” the first phase 2 trial to bring the benefits of phototherapy for MS. It is a placebo-controlled trial that will be conducted within a real-world MS population.
Category:
Complementary And Alternative Therapies
Thursday, May 30, 2024: 5:00 PM – 7:00 PM, Exhibit Hall AB
Booth Details
Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures
Discover how the comparison between the qualitative ratings of atrophy and normative brain volume measures can help us track MS disease progression more accurately.
We will present how the MOVING-MS study captured the clinical utility of the Octave platform, and it’s positive impact on patients’ clinical outcomes.
Poster Presentation Details
